RxDoctor Payments Data

Saint Adeogba, MD

Pain Medicine · Little Rock, ARNPI 1265587869

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.9%), education and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Spinal Simplicity, LLC at 28.1% of the total. Reporting peaked in 2021 at $2,172 and has fallen 85.7% since, to $310 in 2025.

$6,366in general payments, 2019–2025

Across 157 payments — averaging $40.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Simplicity, LLC$2K
  • Boston Scientific$1K
  • SPR Therapeutics, Inc$606
  • AbbVie$368
  • Amgen$317
  • Collegium Pharmaceutical, Inc.$271
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$1,09417%
  • Food & beverage$3,81160%
  • Education$1,46123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,366 in reported general payments places this provider in the 70th percentile of 53 pain medicine providers in Arkansas.

See all pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$21,249
Medicare patients
33
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl18$14,362
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen413$12,634
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl116$12,245
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen209$5,955
Gabapentin152$2,666
Buprenorphine16$2,587
Pregabalin74$1,868
Lidocaine13$1,492
Oxycodone Hcl106$1,459
Acetaminophen-CodeineAcetaminophen With Codeine59$1,436
Fentanyl12$1,423
Celecoxib11$1,372
Naloxone Hcl19$1,320
Cyclobenzaprine Hcl61$1,308
Naproxen16$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$271$14,36218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 53 pain medicine providers in Arkansas.

Other pain medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →